Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting

Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting
Biomea Fusion unveils diabetes data

Biomea Fusion has presented new data from the Phase II COVALENT-112 study at the 86th Scientific Sessions of the American Diabetes Association, focusing on icovamenib in people with type 1 diabetes.

The data, delivered by Dr. Juan Pablo Frías, suggest that icovamenib may offer promising new treatment avenues for patients. The study is part of Biomea Fusion's ongoing efforts to advance novel therapies for diabetes and metabolic disorders. Further details on efficacy and safety outcomes are awaited as the research progresses.

Biomea Fusion recently reported promising Phase II COVALENT-112 data supporting ico as a potential first-in-class therapy option for type 1 diabetes, according to a prior update from the company. Earlier this year, Biomea Fusion also engaged with global industry leaders to explore new collaboration opportunities at the BIO International Convention held in June. These activities reflect the company’s continued focus on advancing therapies for diabetes and metabolic disorders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.